Asieris Pharmaceuticals launches CEVIRA in China, challenging surgical dominance in CIN2 therapy
China approves CEVIRA, the first non-invasive therapy for CIN2 cervical precancer. Discover what this means for treatment pathways and global adoption.
China approves CEVIRA, the first non-invasive therapy for CIN2 cervical precancer. Discover what this means for treatment pathways and global adoption.